Elia Seguí, MD
@eliasegui.bsky.social
Breast Medical Oncologist | Born and raised @hospitalclinic | Research fellow @DFCI_BreastOnc/Harvard Med School | PhD student Translational Genomics @IDIBAPS | 🧬 Main focus: breast oncoIogy, IO and biomarkers.
Reposted by Elia Seguí, MD
Meet Dr. Elia Seguí (@eliasegui.bsky.social), a new Advanced Fellow at the Breast Oncology Center at Dana-Farber. Dr. Seguí specializes in #BreastCancer and #ImmunoOncology. She finds immense fulfillment in combining patient care with academic research.
January 15, 2025 at 2:56 PM
Meet Dr. Elia Seguí (@eliasegui.bsky.social), a new Advanced Fellow at the Breast Oncology Center at Dana-Farber. Dr. Seguí specializes in #BreastCancer and #ImmunoOncology. She finds immense fulfillment in combining patient care with academic research.
Reposted by Elia Seguí, MD
Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️
So how can we ever achieve #gender #equality?
We discuss various strategies in this #Cell Commentary
#WomeninSTEM
www.cell.com/cell/fulltex...
🧵 1/
So how can we ever achieve #gender #equality?
We discuss various strategies in this #Cell Commentary
#WomeninSTEM
www.cell.com/cell/fulltex...
🧵 1/
November 25, 2024 at 12:38 PM
Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️
So how can we ever achieve #gender #equality?
We discuss various strategies in this #Cell Commentary
#WomeninSTEM
www.cell.com/cell/fulltex...
🧵 1/
So how can we ever achieve #gender #equality?
We discuss various strategies in this #Cell Commentary
#WomeninSTEM
www.cell.com/cell/fulltex...
🧵 1/
Reposted by Elia Seguí, MD
Insightful translational study on chemo+IO in eTNBC dissecting chemo response vs IO response! Well done GBG! @cellpressnews.bsky.social #bcsm @oncoalert.bsky.social
Correlative analysis of GeparNuevo #TNBC neoadj clinical trial by Denkert et al:
➡️Expression analyses of tumor biopsies at 3 time points
➡️Confirm role of immune & prolif signatures
➡️Stromal signature assoc w immunotherapy resistance
@oncoalert.bsky.social #BCSM
www.cell.com/cell-reports...
➡️Expression analyses of tumor biopsies at 3 time points
➡️Confirm role of immune & prolif signatures
➡️Stromal signature assoc w immunotherapy resistance
@oncoalert.bsky.social #BCSM
www.cell.com/cell-reports...
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
Denkert et al. evaluate the longitudinal changes in tumor tissue of triple-negative
breast cancer in a clinical trial cohort treated with neoadjuvant immunotherapy plus
chemotherapy. The role of diffe...
www.cell.com
November 22, 2024 at 9:39 AM
Insightful translational study on chemo+IO in eTNBC dissecting chemo response vs IO response! Well done GBG! @cellpressnews.bsky.social #bcsm @oncoalert.bsky.social
Reposted by Elia Seguí, MD
For me it’s control over what I choose to expose myself to on a daily basis. I have thought a lot about quitting social media all together due to its negative impacts.
Looking for a space to share medical knowledge and research, be up to date. I don’t need an echo chamber but I do need sanity.
Looking for a space to share medical knowledge and research, be up to date. I don’t need an echo chamber but I do need sanity.
‘A place of joy’: why scientists are joining the rush to Bluesky
November 22, 2024 at 2:51 PM
For me it’s control over what I choose to expose myself to on a daily basis. I have thought a lot about quitting social media all together due to its negative impacts.
Looking for a space to share medical knowledge and research, be up to date. I don’t need an echo chamber but I do need sanity.
Looking for a space to share medical knowledge and research, be up to date. I don’t need an echo chamber but I do need sanity.
Definitely a must-read for anyone interested in the interplay between ER signaling and the tumor immune microenvironment. Incredible work by @ccortimd.bsky.social 👏👏
👉 Check it out here: doi.org/10.1016/j.ct...
👉 Check it out here: doi.org/10.1016/j.ct...
November 21, 2024 at 4:32 PM
Definitely a must-read for anyone interested in the interplay between ER signaling and the tumor immune microenvironment. Incredible work by @ccortimd.bsky.social 👏👏
👉 Check it out here: doi.org/10.1016/j.ct...
👉 Check it out here: doi.org/10.1016/j.ct...
Reposted by Elia Seguí, MD
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
November 17, 2024 at 11:04 PM
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
Seeing this explosion of activity on BlueSky, I can’t help but feel excited about the possibilities. Let’s make this a space dedicated to vibrant scientific discussions, true collaboration, and inclusion for everyone 🧬
November 17, 2024 at 10:27 PM
Seeing this explosion of activity on BlueSky, I can’t help but feel excited about the possibilities. Let’s make this a space dedicated to vibrant scientific discussions, true collaboration, and inclusion for everyone 🧬
Reposted by Elia Seguí, MD
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 17, 2024 at 8:01 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!